Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA

Scandinavian Journal of Immunology

Volumn 67, Issue 2, 2008, Pages 113-120

  Steinaa, L ^a   Rasmussen, P B ^a   Gautam, A ^a   Mouritsen, S ^a  

^a Pharmexa AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA VACCINE; EPITOPE; OVALBUMIN; TETANUS TOXIN;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CELL PROLIFERATION; DNA; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; IMMUNIZATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXIN; VACCINES, DNA;

EID: 38149040809     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02045.x     Document Type: Article

References (45)

1. Baxevanis CN, Sotiriadou NN, Gritzapis AD et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 2006 55 : 85 95.
2. Ciardiello F, De Vita F. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. Prog Drug Res 2005 63 : 93 114.
3. Matsueda S, Takedatsu H, Yao A et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 2005 11 : 6933 43.
4. Perez EA, Suman VJ, Rowland KM et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG Study 983252. Clin Breast Cancer 2005 6 : 425 32.
5. Todorova K, Zoubak S, Mincheff M, Kyurkchiev S. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. Anticancer Res 2005 25 : 4727 32.
6. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995 3 : 407 15.
7. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000 13 : 829 40.
8. Sandberg JK, Franksson L, Sundback J, et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol 2000 165 : 25 33.
9. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997 186 : 65 70.
10. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998 393 : 474 8.
11. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998 393 : 478 80.
12. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 393 : 480 3.
13. Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 2003 171 : 6339 43.
14. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003 421 : 852 6.
15. Kirberg J, Bruno L, von Boehmer H. CD4+8- help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur J Immunol 1993 23 : 1963 7.
16. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996 184 : 863 71.
17. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002 32 : 2199 207.
18. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999 5 : 774 9.
19. Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999 11 : 483 93.
20. Miller JF, Basten A. Mechanisms of tolerance to self. Curr Opin Immunol 1996 8 : 815 21.
21. Zinkernagel RM, Pircher HP, Ohashi P, et al. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev 1991 122 : 133 71.
22. Nemazee D, Weigert M. Revising B cell receptors. J Exp Med 2000 191 : 1813 7.
23. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989 337 : 562 6.
24. Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993 72 : 325 35.
25. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991 353 : 765 9.
26. Fang W, Weintraub BC, Dunlap B, et al. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 1998 9 : 35 45.
27. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A 1996 93 : 2264 71.
28. Hippen KL, Schram BR, Tze LE, Pape KA, Jenkins MK, Behrens TW. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J Immunol 2005 175 : 909 16.
29. Gaudin E, Hao Y, Rosado MM, Chaby R, Girard R, Freitas AA. Positive selection of B cells expressing low densities of self-reactive BCRs. J Exp Med 2004 199 : 843 53.
30. Dalum I, Jensen MR, Hindersson P, Elsner HI, Mouritsen S. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996 157 : 4796 804.
31. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999 17 : 666 9.
32. Hertz M, Mahalingam S, Dalum I, et al. Active vaccination against il-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001 167 : 3792 9.
33. Renard V, Sonderbye L, Ebbehoj K, et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 2003 171 : 1588 95.
34. Lo D, Freedman J, Hesse S, Palmiter RD, Brinster RL, Sherman LA. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 1992 22 : 1013 22.
35. Kurts C, Sutherland RM, Davey G, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 1999 96 : 12703 7.
36. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996 184 : 923 30.
37. Steinaa L, Rasmussen PB, Wegener AM, et al. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol 2005 175 : 329 34.
38. Steinaa L, Rasmussen PB, Rygaard J, Mouritsen S, Gautam A. Generation of autoreactive CTL by tumor vaccines containing foreign T helper epitopes. Scand J Immunol 2007 65 : 240 48.
39. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988 54 : 777 85.
40. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989 19 : 2237 42.
41. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J Immunol 1998 161 : 6532 6.
42. Duch M, Tolstrup A, Dalum I, Jespersen T, Mouritsen S, Pedersen FS. Functional testing of a bicistronic retroviral vector for intracellular peptide production. BioTechniques 1999 26 : 1032 4.
43. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997 186 : 239 45.
44. Morgan DJ, Kreuwel HT, Sherman LA. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol 1999 163 : 723 7.
45. Guerder S, Matzinger P. A fail-safe mechanism for maintaining self-tolerance. J Exp Med 1992 176 : 553 64.